Status:
COMPLETED
Study Evaluating DVS SR in Patients With Fibromyalgia Syndrome
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Fibromyalgia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The primary objective is to evaluate the long-term safety of desvenlafaxine succinate sustained-release (DVS SR) during open-label treatment in adult outpatients with fibromyalgia syndrome.
Detailed Description
Patients completing study 3151A4-327 have the opportunity to be treated with DVS SR during the 6 month extension study.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Outpatients who have completed double-blind treatment in study 3151A4-327 for fibromyalgia Syndrome with no major protocol violations and no events that would preclude the patient's entry into the long-term open-label study.
- Women of childbearing potential must have a negative serum pregnancy test result at study start.
- Exclusion criteria:
- Presence of any new/and or clinically important medical condition that might compromise patient's safety.
- Use of prohibited treatment.
- Meets any of the exclusion criteria listed for study 3151A4-327.
Exclusion
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
June 1 2007
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT00424892
End Date
June 1 2007
Last Update
December 6 2007
Active Locations (59)
Enter a location and click search to find clinical trials sorted by distance.
1
Huntsville, Alabama, United States, 35801
2
Mobile, Alabama, United States, 36608
3
Phoenix, Arizona, United States, 85016
4
Anaheim, California, United States, 92801